Citrulline for Children Undergoing Cardiopulmonary Bypass Surgery

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

December 31, 2003

Primary Completion Date

January 31, 2006

Study Completion Date

December 31, 2009

Conditions
Cardiovascular DiseasesHeart DiseasesHeart Defects, Congenital
Interventions
DRUG

Citrulline

Phase I - 150mg/kg IV bolus after initiation of cardiopulmonary bypass with dosage escalation study 50mg/kg, 100mg/kg, 150mg/kg IV at 6, 12, 24, 48 hours post operative. Phase II - 150mg/kg IV bolus after initiation of cardiopulmonary bypass with 9mg/kg/hr continuous IV starting 4 hours post bolus and infusing for 48 hours or discharge from PCCU.

Trial Locations (1)

37212

Vanderbilt University, Nashville

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Vanderbilt University

OTHER

NCT00201214 - Citrulline for Children Undergoing Cardiopulmonary Bypass Surgery | Biotech Hunter | Biotech Hunter